Close Menu
  • Home
  • AI
  • Business
  • Market
    • Media
      • News
    • Politics
  • Sports
  • USA
  • World
    • Local
  • Breaking News
  • Health
  • Entertainment & Lifestyle

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated

What's Hot

Dave Parker, Hall of Fame outfielder nicknamed ‘the Cobra,’ dies at 74

Stranger Things Cast Teases Fifth & Final Season

Funeral for brain-dead woman kept alive due to abortion law held Saturday in Georgia

Facebook X (Twitter) Instagram
  • Home
  • About Us
  • Advertise With Us
  • Contact Us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
Facebook X (Twitter) Instagram
BLMS Media | Breaking News, Politics, Markets & World Updates
  • Home
  • AI
  • Business
  • Market
    • Media
      • News
    • Politics
  • Sports
  • USA
  • World
    • Local
  • Breaking News
  • Health
  • Entertainment & Lifestyle
BLMS Media | Breaking News, Politics, Markets & World Updates
Home » Health Secretary Shares Concerns About Efficacy of Novavax COVID-19 Vaccine After FDA Delay
USA

Health Secretary Shares Concerns About Efficacy of Novavax COVID-19 Vaccine After FDA Delay

BLMS MEDIABy BLMS MEDIAApril 11, 2025No Comments3 Mins Read
Share Facebook Twitter Pinterest Telegram LinkedIn Tumblr Email Copy Link
Follow Us
Google News Flipboard
Share
Facebook Twitter LinkedIn Pinterest Email Copy Link


Robert F. Kennedy Jr. said the vaccine is not effective.

Health Secretary Robert F. Kennedy Jr. said in a new interview that Novavax’s COVID-19 vaccine is not effective, his first comments since regulators missed a deadline to approve the shot.

“We’re looking at that vaccine. It is a single antigen vaccine, and for respiratory illnesses, the single antigen vaccines have never worked,” Kennedy told CBS in an interview released on April 9.

The Food and Drug Administration (FDA) was supposed to decide whether to grant Novavax’s license application by April 2, the Maryland-based company has said. The firm makes one of the three COVID-19 vaccines available in the United States, and the only one that does not use messenger ribonucleic acid technology.

The FDA has not said why the deadline passed without a decision.

An official with the Department of Health and Human Services (HHS), which Kennedy heads, previously told The Epoch Times in an email that “any delays to the FDA’s independent review process for the Novavax are a result of scientific review to ensure safety and efficacy.” The FDA is part of HHS.

Kennedy was asked in the new interview if the delay stemmed from a lack of personnel, after the departure of Dr. Peter Marks, among others. Marks led the FDA’s office in charge of reviewing vaccines.

Related Stories

FDA Deadline for Novavax’s COVID-19 Vaccine Passes Without Decision
RFK Jr. Says US Is Launching Massive Effort to Pinpoint Cause of Spiking Autism Rates

“We are actually shifting our priorities to multiple antigen vaccines. And NIH is already working on a number of those,” Kennedy said, referring to another HHS division, the National Institutes of Health.

In an April 10 statement, Novavax said, “As we have previously stated, we believe that our Biologics License Application (BLA) for our COVID-19 vaccine included robust Phase 3 clinical trial data that showed our vaccine is safe and effective for the prevention of COVID-19.”
It pointed to a clinical trial conducted by the company that recorded 14 cases of COVID-19 among vaccine recipients and 63 cases among recipients of a placebo, as well as a second trial that found the efficacy of the vaccine was 79.5 percent among adolescents.

“We have not yet received an official response from the U.S. Food and Drug Administration regarding the status of our BLA,” the company said.

The other two COVID-19 vaccines that are cleared by the FDA are made by Moderna and Pfizer. Both are built on messenger ribonucleic acid technology, or mRNA, platforms.

The FDA in 2024, in its most recent action on the vaccines, cleared updated COVID-19 vaccines from all three manufacturers, stating that older versions were not as effective against newer COVID-19 strains. Novavax’s updated shot received emergency authorization, as opposed to approval.

Novavax shares dropped from $6.95 on April 9 to $5.12 on April 10, though the price had partially rebounded to $5.61 on Friday.



Source link

Follow on Google News Follow on Flipboard
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Copy Link
Previous ArticleSpot AI introduces the world’s first universal AI agent builder for security cameras
Next Article Trump Administration Says It Is Not Required to Bring Wrongly Deported Man Back to US
BLMS MEDIA
  • Website

Related Posts

‘State Organs’ Film Receives Humanitarian Award for Highlighting Ongoing Abuse in China

June 10, 2025

Paternity Leave in UK One of Worst in Developed World, Committee Finds

June 10, 2025

Overhaul of Thames Water Comes Amid Privatisation, Foreign Ownership Scrutiny

June 10, 2025
Add A Comment
Leave A Reply Cancel Reply

Top Posts

Nova Scotia: Siblings Lily, 6, and Jack, 4, have been missing in rural Canada for four days

May 6, 202515 Views

Families of Air India crash victims give DNA samples to help identify loved ones

June 13, 20258 Views

Australia’s center-left Labor Party retains power as conservative leader loses seat, networks report

May 3, 20254 Views

These kibbutzniks used to believe in peace with Palestinians. Their views now echo Israel’s rightward shift

May 2, 20254 Views
Don't Miss

Meta reportedly hires four more researchers from OpenAI

By BLMS MEDIAJune 28, 20250

Looks like Meta isn’t done poaching talent from OpenAI. Earlier this week, TechCrunch reported that…

Week in Review:  Meta’s AI recruiting blitz

Vitalik Buterin has reservations about Sam Altman’s World project

Anthropic’s Claude AI became a terrible business owner in experiment that got ‘weird’

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated

Our Picks

Dave Parker, Hall of Fame outfielder nicknamed ‘the Cobra,’ dies at 74

Stranger Things Cast Teases Fifth & Final Season

Funeral for brain-dead woman kept alive due to abortion law held Saturday in Georgia

Welcome to BLMS Media — your trusted source for news, insights, and stories that shape our world.

At BLMS Media, we are committed to delivering timely, accurate, and in-depth information across a wide range of topics. Whether you’re looking for breaking news, political analysis, market trends, or global developments, we bring you the stories that matter — with clarity, integrity, and perspective.

Facebook X (Twitter) Instagram Pinterest
  • Home
  • About Us
  • Advertise With Us
  • Contact Us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
© 2025 blmsmedia. Designed by blmsmedia.

Type above and press Enter to search. Press Esc to cancel.